NASDAQ:RNAZ TransCode Therapeutics (RNAZ) Stock Price, News & Analysis $0.25 0.00 (-1.45%) (As of 09:45 AM ET) Add Compare Share Share Today's Range$0.25▼$0.2550-Day Range$0.23▼$0.9852-Week Range$0.22▼$128.00Volume58,988 shsAverage Volume1.10 million shsMarket Capitalization$4.35 millionP/E RatioN/ADividend YieldN/APrice Target$3.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get TransCode Therapeutics alerts: Email Address TransCode Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,090.5% Upside$3.00 Price TargetShort InterestHealthy1.02% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.34Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.05) to ($0.47) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.99 out of 5 stars 3.5 Analyst's Opinion Consensus RatingTransCode Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageTransCode Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about TransCode Therapeutics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.02% of the float of TransCode Therapeutics has been sold short.Short Interest Ratio / Days to CoverTransCode Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in TransCode Therapeutics has recently decreased by 89.28%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldTransCode Therapeutics does not currently pay a dividend.Dividend GrowthTransCode Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RNAZ. Previous Next 3.0 News and Social Media Coverage News SentimentTransCode Therapeutics has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for TransCode Therapeutics this week, compared to 1 article on an average week.Search Interest7 people have searched for RNAZ on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days.MarketBeat Follows2 people have added TransCode Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, TransCode Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.47% of the stock of TransCode Therapeutics is held by insiders.Read more about TransCode Therapeutics' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for TransCode Therapeutics are expected to grow in the coming year, from ($2.05) to ($0.47) per share.Price to Book Value per Share RatioTransCode Therapeutics has a P/B Ratio of 0.10. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about TransCode Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchThe Last Time Stocks Looked Like This, They Didn’t Move For 16 YearsThere is nothing the Federal Reserve can do on September 18 to stop what's coming next for U.S. stocks.Click here to view my new presentation now. About TransCode Therapeutics Stock (NASDAQ:RNAZ)TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.Read More RNAZ Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RNAZ Stock News HeadlinesSeptember 9 at 3:51 AM | americanbankingnews.comTransCode Therapeutics (NASDAQ:RNAZ) Earns Buy Rating from HC WainwrightSeptember 5, 2024 | markets.businessinsider.comBuy Rating for TransCode Therapeutics Backed by NIH Grant and Promising Treatment EfficacySeptember 10, 2024 | Stansberry Research (Ad)The Last Time Stocks Looked Like This, They Didn’t Move For 16 YearsThere is nothing the Federal Reserve can do on September 18 to stop what's coming next for U.S. stocks.September 5, 2024 | globenewswire.comTransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead CandidateAugust 15, 2024 | finanznachrichten.deTransCode Therapeutics, Inc.: TransCode Therapeutics Announces Phase 1 Clinical Trial InitiationAugust 15, 2024 | markets.businessinsider.comTransCode Therapeutics Announces Phase 1 Clinical Trial InitiationAugust 15, 2024 | investorplace.comRNAZ Stock Earnings: TransCode Therapeutics Misses EPS for Q2 2024July 24, 2024 | globenewswire.comTransCode Therapeutics, Inc. Announces Closing of Public OfferingSeptember 10, 2024 | Stansberry Research (Ad)The Last Time Stocks Looked Like This, They Didn’t Move For 16 YearsThere is nothing the Federal Reserve can do on September 18 to stop what's coming next for U.S. stocks.July 24, 2024 | benzinga.comWhy Transcode Therapeutics (RNAZ) Stock Is Down 60%July 23, 2024 | investorplace.comWhy Is TransCode Therapeutics (RNAZ) Stock Down 62% Today?July 23, 2024 | finance.yahoo.comBiotechnology (Industry) (^YH20610010)July 22, 2024 | markets.businessinsider.comTransCode Therapeutics Prices Public Offering Of 10 Mln Shares At $0.30/shrJuly 22, 2024 | globenewswire.comTransCode Therapeutics, Inc. Announces Pricing of Public OfferingJuly 22, 2024 | globenewswire.comTransCode Therapeutics, Inc. Announces Proposed Public Offering of Common StockJune 10, 2024 | globenewswire.comNasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing RequirementsJune 3, 2024 | investorplace.comRNAZ Stock Earnings: TransCode Therapeutics Misses EPS for Q1 2024May 29, 2024 | globenewswire.comTransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138See More Headlines Receive RNAZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TransCode Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/14/2024Today9/10/2024Next Earnings (Estimated)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RNAZ CUSIPN/A CIK1829635 Webwww.transcodetherapeutics.com Phone857-837-3099FaxN/AEmployees9Year FoundedN/APrice Target and Rating Average Stock Price Target$3.00 High Stock Price Target$3.00 Low Stock Price Target$3.00 Potential Upside/Downside+1,071.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-18,550,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-597.48% Return on Assets-260.31% Debt Debt-to-Equity RatioN/A Current Ratio1.25 Quick Ratio1.25 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.62 per share Price / Book0.10Miscellaneous Outstanding Shares17,270,000Free Float6,525,000Market Cap$4.42 million OptionableNot Optionable Beta0.47 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Thomas A. Fitzgerald M.B.A. (Age 72)Interim CEO, CFO, President, VP of Administration & Director Comp: $358.14kDr. Philippe P. Calais Ph.D. (Age 65)Pharm., Pharm.D., Executive Chairman of the Board Comp: $102.5kDr. Zdravka Medarova Ph.D. (Age 49)Co-Founder & Chief Scientific Officer Dr. Anna Moore Ph.D. (Age 62)Co-Founder, Scientific Advisor & Member of Scientific Advisory Board Ms. Susan Duggan M.B.A.R.N., Senior Vice President of OperationsDr. Daniel R. Vlock M.D. (Age 72)Chief Medical Officer More ExecutivesKey CompetitorsBioCardiaNASDAQ:BCDAElevai LabsNASDAQ:ELABBiofronteraNASDAQ:BFRIOragenicsNYSE:OGENCERo TherapeuticsNASDAQ:CEROView All CompetitorsInsidersRobert Michael DudleyBought 2,450 shares on 9/28/2023Total: $49,980.00 ($20.40/share)Thomas A FitzgeraldBought 1,233 shares on 9/28/2023Total: $25,153.20 ($20.40/share)View All Insider Transactions RNAZ Stock Analysis - Frequently Asked Questions How have RNAZ shares performed this year? TransCode Therapeutics' stock was trading at $6.5920 on January 1st, 2024. Since then, RNAZ stock has decreased by 96.2% and is now trading at $0.2520. View the best growth stocks for 2024 here. How were TransCode Therapeutics' earnings last quarter? TransCode Therapeutics, Inc. (NASDAQ:RNAZ) released its quarterly earnings results on Wednesday, August, 14th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.58) by $0.16. When did TransCode Therapeutics' stock split? TransCode Therapeutics shares reverse split on Tuesday, January 16th 2024. The 1-40 reverse split was announced on Tuesday, January 16th 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, January 16th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did TransCode Therapeutics IPO? TransCode Therapeutics (RNAZ) raised $25 million in an initial public offering (IPO) on Friday, July 9th 2021. The company issued 6,250,000 shares at $4.00 per share. How do I buy shares of TransCode Therapeutics? Shares of RNAZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RNAZ) was last updated on 9/10/2024 by MarketBeat.com Staff From Our PartnersYour Crypto Future is at StakeWhat if I told you that bananas could make you a millionaire? No, this isn't a joke – I'm talking about the...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredKamala’s Secret 3-Word Plan to Destroy America… Are You Prepared?America’s Slow Decline into Hell As Kamala Harris rises to power, her 3-word agenda threatens every America...Banyan Hill Publishing | SponsoredWarning For Nvidia HoldersHow The Boeing Disasters Could Hit Nvidia Investors You may have heard about Boeing planes falling apart mi...Stansberry Research | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredMike Huckabee Puts His Faith in This to Protect His RetirementMike Huckabee's Urgent Warning: Safeguard Your Financial Future NowAmerican Hartford Gold Group | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TransCode Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TransCode Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
